Skip to Content
Merck
All Photos(1)

Documents

SML2653

Sigma-Aldrich

Sorafenib

≥98% (HPLC), powder, kinase inhibitor

Synonym(s):

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, BAY 43-9006, BAY43-9006, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H16ClF3N4O3
CAS Number:
284461-73-0
Molecular Weight:
464.82
MDL number:
MFCD06411450
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Sorafenib, ≥98% (HPLC)

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

InChI key

MLDQJTXFUGDVEO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Sorafenib (BAY 43-9006) is an orally active kinase inhibitor that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-ß), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Danger

Hazard Statements

H360FD,H362,H372,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

Erlotinib hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML2156

Erlotinib hydrochloride

Erastin ≥98% (HPLC)

Sigma-Aldrich

E7781

Erastin

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

2,4,6-Tris(dimethylamino)-1,3,5-triazine 96%

Sigma-Aldrich

549835

2,4,6-Tris(dimethylamino)-1,3,5-triazine

Safranal ≥90%, stabilized

Sigma-Aldrich

W338907

Safranal

DL-Buthionine-(S,R)-sulfoximine

Sigma-Aldrich

B2640

DL-Buthionine-(S,R)-sulfoximine

Midostaurin hydrate ≥98% (HPLC), solid

Sigma-Aldrich

M1323

Midostaurin hydrate

Thioridazine hydrochloride ≥99%

Sigma-Aldrich

T9025

Thioridazine hydrochloride

FIN56 ≥98% (HPLC)

Sigma-Aldrich

SML1740

FIN56

Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder

Sigma-Aldrich

V2264

Vinorelbine ditartrate salt hydrate

Paul T C Wan et al.
Cell, 116(6), 855-867 (2004-03-24)
Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal
Shengnan Liu et al.
Cancer letters, 453, 74-83 (2019-04-01)
Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after
Xudong Gao et al.
OncoTargets and therapy, 12, 1629-1640 (2019-03-19)
Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect
Jeong-Ju Yoo et al.
International journal of molecular sciences, 20(6) (2019-03-17)
This study aimed to examine whether inhibition of hexokinase (HK)-II activity enhances the efficacy of sorafenib in in-vivo models of hepatocellular carcinoma (HCC), and to evaluate the prognostic implication of HK-II expression in patients with HCC. We used 3-bromopyruvate (3-BP)
Mater H Mahnashi et al.
Pharmaceuticals (Basel, Switzerland), 15(2) (2022-02-27)
Over the past few decades, the development of broad-spectrum anticancer agents with anti-angiogenic activity has witnessed considerable progress. In this study, a new series of pyrazolo[3,4-d]pyrimidines based on a phenylfuroxan scaffold were designed, synthesized, and evaluated, in terms of their
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service